Evolus Announces "Extra-Strength" 40U Formulation Of Jeuveau Demonstrates Effects Lasting 26 Weeks In Phase II Data Presented At 2023 American Society Of Dermatologic Surgery Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Evolus has announced that its 'extra-strength' 40U formulation of Jeuveau has shown effects lasting 26 weeks in Phase II data presented at the 2023 American Society of Dermatologic Surgery Annual Meeting.
November 07, 2023 | 10:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evolus' announcement of successful Phase II data for its 'extra-strength' 40U formulation of Jeuveau may positively impact its stock price.
The announcement of successful Phase II data for a product typically indicates progress and potential future revenue, which can positively impact a company's stock price. Given that the news is directly about Evolus and its product, the relevance is high.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100